Taking aim at best practices.
AUA2021 featured a number of sessions highlighting updated guidelines or outlining new guidelines in the specialty of urology.
A new guideline published in January 2021 combines and updates two earlier guidelines on follow-up for clinically localized renal neoplasms (2013) and on evaluation and management of renal masses and localized renal cancer (2017). Four of the recent guideline authors discussed the updated guideline during the session “Evaluation and Management of Localized Renal Masses: A Case-Based Approach.”
AUA’s new Advanced Prostate Cancer Guidelines were outlined during the session “AUA Guidelines: Advanced Prostate Cancer,” which provided an overview of Parts I and II of the two-part guideline series dedicated to advanced prostate cancer treatment. The session served as a preview to the session “AUA Guidelines on Advanced/Metastatic/Castration-Resistant Prostate Cancer.”
Last week’s instructional course “Refractory Overactive Bladder: How to Select Third-Line Therapies and Optimize Outcomes” described the new 2019 American Urological Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction guideline provides first-, second- and third-line evidence-based treatment approaches for the diagnosis and treatment of non-neurogenic overactive bladder.
The guideline on non-muscle invasive bladder cancer from the AUA and the Society of Urologic Oncology, which was published in 2016, was amended and updated in 2020. The newest version includes new treatment options and proven strategies when Bacillus Calmette-Guérin is scarce. These updates were outlined in the session “Guidelines and Beyond: Case-Based Approach to Non-Muscle Invasive Bladder Cancer.”
Visit AUA2021 Daily News Online for more articles.